Sarcomas

Long-term follow-up showed that trabectedin (Yondelis) was associated with high rates of survival and clinical benefit rate for patients with advanced high grade soft tissue sarcomas.

Cediranib was associated with significantly reduced tumor burden and superior progression-free survival compared with placebo in patients with alveolar soft part sarcoma.

As clinicians have gained an improved understanding of the biology of soft-tissue sarcoma malignancies, the ability to better distinguish and identify subtypes has extended the hope of targeted treatment options.

Neeta Somaiah, MD, assistant professor, Department of Sarcoma Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the expression of NY-ESO-1 in patients with soft tissue sarcoma.

Giovanni Grignani, MD, medical oncologist, Candiolo Cancer Institute IRCCS, discusses the intended patient population for trabectedin (Yondelis) in the treatment of sarcoma.

Lisa H. Butterfield, PhD, professor of medicine, surgery, and immunology, director, University of Pittsburgh Immunologic Monitoring and Cellular Products Laboratory, University of Pittsburgh, president of the Society for Immunotherapy of Cancer, discusses the potential role for immunotherapy in the treatment of patients with sarcoma.

Aldoxorubicin was associated with superior progression-free survival compared with standard chemotherapy regimens and may be a viable treatment alternative for some patients with relapsed or refractory soft tissue sarcomas, according to results from a phase III international study.

Breelyn Wilky, MD, an associate professor of Medicine, Sylvester Comprehensive Cancer Care, University of Miami Health System, discusses how to determine which treatment a patient with sarcoma should receive.

Epizyme announced today that the FDA has granted orphan drug designation to its EZH2-inhibitor tazemetostat for the treatment of adults with INI1-negative epithelioid sarcoma.

Dual checkpoint inhibition with nivolumab (Opdivo) plus ipilimumab (Yervoy) induced an objective response rate of 16% in patients with heavily treated, unselected, metastatic sarcoma, according to findings from the phase II ALLIANCE A091401 trial.

Neeta Somaiah, MD, assistant professor, Department of Sarcoma Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses phase I findings of CMB305 in patients with NY-ESO-1–positive recurrent soft tissue sarcoma.

Lisa H. Butterfield, PhD, professor of medicine, surgery, and immunology, director, University of Pittsburgh Immunologic Monitoring and Cellular Products Laboratory, University of Pittsburgh, president of the Society for Immunotherapy of Cancer, discusses a clinical trial exploring the PD-1 inhibitor pembrolizumab (Keytruda) in multiple subtypes of sarcoma.

Giovanni Grignani, MD, medical oncologist, Candiolo Cancer Institute IRCCS, discusses the future of treatments for patients with soft tissue sarcoma.

Charles Catton, MD, professor, Department of Radiation Oncology University of Toronto, discusses quality assurance with radiation therapy for patients with sarcoma.

Adjuvant radiotherapy was associated with improved survival for patients with non-retroperitoneal abdominal soft tissue sarcomas (NRA-STS), but the addition of chemotherapy did not confer a similar survival benefit.

Researchers at Istanbul University Institute of Oncology have concluded that patients with high-risk extremity soft tissue sarcoma have similar 3-year outcomes whether they are assigned to neoadjuvant sequential chemoradiotherapy or radiation alone.

Bernd Kasper, MD, PhD, professor, Universitätsmedizin Mannheim, Mannheim, discusses future treatment approaches in the field of sarcoma and the potential role of imatinib (Gleevac).

Chemotherapy with doxorubicin and ifosfamide improved progression-free survival and tumor response compared with doxorubicin alone in soft tissue sarcoma, but the combination may be best suited for young, fit patients.

Chinese researchers have concluded that the oral VEGFR2 inhibitor apatinib demonstrated efficacy with tolerable toxicity in a small study of patients with stage IV sarcoma, according to results published in Oncotarget.

Kiran Turaga, MD, MPH, surgical oncologist, University of Chicago Cancer Center, discusses the current surgical setting of sarcoma.

Symantha Melemed, global product team lead, Oncology Business Unit, Eli Lilly & Company, discusses the impact of the FDA approval of olaratumab (Lartruvo) in patients with soft tissue sarcoma

Suzanne George, MD, assistant professor of Medicine, Harvard Medical School, clinical director, Center for Sarcoma and Bone Oncology, Dana-Farber Cancer Institute, discusses a study exploring the efficacy of a PD-1 inhibitor in patients with uterine leiomyosarcoma.

Researchers at MD Anderson Cancer Center believe that including clinical genomic profiling into sarcoma management could result in more precise diagnosis and subclassification of the disease.

Suzanne George, MD, discusses an exceptional responder to pembrolizumab in leiomyosarcoma and the significance of these findings for further immunotherapy advances in the field.